Loading patent…
AssigneeHadasit Medical Research Services and Development Ltd.
InventorsMichal LOTEM, Ori STERN, Shiri KLEIN, Galit EISENBERG, Elad ZISMAN
Estimating the term…
The present disclosure relates to manipulation of splicing of the Fas (tumor necrosis factor (TNF) receptor superfamily, member 6) gene in non-naïve cell of the T lineage for enhanced skipping of exon 6. The manipulated non-naïve cells predominantly express a soluble form of Fas (sFas) and display reduced expression of the membranal Fas (mFas), increased cytokine secretion, increased expression of activation markers, increased cell survival, increased cytotoxicity, and/or reduced expression of exhaustion markers. The present disclosure further provides specific splicing modulatory agents comprising gene editing systems and/or splice switching antisense oligonucleotide (SSO), methods and therapeutic uses thereof.
A non-naïve cell of the T lineage manipulated for enhanced skipping of exon 6 of the Fas (tumor necrosis factor (TNF) receptor superfamily, member 6) gene, or a cell population comprising at least one of said cell, wherein said non-naïve manipulated cell of the T lineage predominantly expresses a soluble form of Fas (sFas).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating, ameliorating, inhibiting or delaying the onset of a pathologic disorder in a mammalian subject, said method comprising the step of administering to said subject an effective amount of at least one of:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-33. (canceled)
A method for improving activity and/or survival of at least one cell of the T lineage, the method comprising the step of contacting said at least one cell with an effective amount of at least one splicing modulating agent comprising at least one nucleic acid molecule or any vector, vehicle, matrix, nano- or micro-particle or composition comprising said at least one agent, said at least one nucleic acid molecule targeting at least one target nucleic acid sequence that participates directly or indirectly in at least one splicing event of the Fas gene, thereby enhancing skipping of exon 6.
(canceled)
(canceled)
-44. (canceled)
A splicing modulating agent comprising at least one nucleic acid molecule or any vector, vehicle, matrix, nano- or micro-particle or composition comprising said at least one agent, said at least one nucleic acid molecule targets at least one target nucleic acid sequence that participates directly or indirectly in at least one splicing event of Fas gene.
-50. (canceled)
Dependencies are inferred from the claim text.